BACKGROUND: The anti-HCV antibody response has not been well characterized during the early phase of HCV infection and little is known about its relationship to the clinical course during this period. METHODS: We analyzed serial anti-HCV antibodies longitudinally obtained from a prospective cohort of 65 patients with acute HCV infection by using a microparticle enzyme immunoassay AxSYM HCV 3.0 (Abbott Diagnostics) during the first 12 months from HCV acquisition in Rio de Janeiro, Brazil. Spontaneous viral clearance (SVC) was defined as undetectable HCV RNA in serum, in the absence of treatment, for three consecutive HCV PCR tests within 12-months of follow-up. RESULTS: Baseline antibody values were similar among patient groups with self-limiting HCV evolution (n = 34) and persistent viremia (n = 31) [median (interquartile range) signal/cut-off ratio (s/co) 78.7 (60.7-93.8) vs. 93.9 (67.8-111.9), p = 0.26]. During 12-months follow-up, patients with acute spontaneous resolving HCV infection showed significantly lower serial antibody response in comparison to individuals progressing to chronic infection [median (interquartile range) s/co 62.7 (35.2-85.0) vs. 98.4 (70.4-127.4), p < 0.0001]. In addition, patients with self-limiting HCV evolution exhibited an expeditious, sharp decline of serial antibody values after SVC in comparison to those measured before SVC [median (interquartile range) s/co 56.0 (25.4-79.3) vs. 79.4 (66.3-103.0), p < 0.0001]. CONCLUSION: Our findings indicate a rapid short-term decline of antibody values in patients with acute spontaneous resolving HCV infection.
BACKGROUND: The anti-HCV antibody response has not been well characterized during the early phase of HCV infection and little is known about its relationship to the clinical course during this period. METHODS: We analyzed serial anti-HCV antibodies longitudinally obtained from a prospective cohort of 65 patients with acute HCV infection by using a microparticle enzyme immunoassay AxSYM HCV 3.0 (Abbott Diagnostics) during the first 12 months from HCV acquisition in Rio de Janeiro, Brazil. Spontaneous viral clearance (SVC) was defined as undetectable HCV RNA in serum, in the absence of treatment, for three consecutive HCV PCR tests within 12-months of follow-up. RESULTS: Baseline antibody values were similar among patient groups with self-limiting HCV evolution (n = 34) and persistent viremia (n = 31) [median (interquartile range) signal/cut-off ratio (s/co) 78.7 (60.7-93.8) vs. 93.9 (67.8-111.9), p = 0.26]. During 12-months follow-up, patients with acute spontaneous resolving HCV infection showed significantly lower serial antibody response in comparison to individuals progressing to chronic infection [median (interquartile range) s/co 62.7 (35.2-85.0) vs. 98.4 (70.4-127.4), p < 0.0001]. In addition, patients with self-limiting HCV evolution exhibited an expeditious, sharp decline of serial antibody values after SVC in comparison to those measured before SVC [median (interquartile range) s/co 56.0 (25.4-79.3) vs. 79.4 (66.3-103.0), p < 0.0001]. CONCLUSION: Our findings indicate a rapid short-term decline of antibody values in patients with acute spontaneous resolving HCV infection.
Authors: A Takaki; M Wiese; G Maertens; E Depla; U Seifert; A Liebetrau; J L Miller; M P Manns; B Rehermann Journal: Nat Med Date: 2000-05 Impact factor: 53.440
Authors: E Jaeckel; M Cornberg; H Wedemeyer; T Santantonio; J Mayer; M Zankel; G Pastore; M Dietrich; C Trautwein; M P Manns Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: L I Nikolaeva; N P Blokhina; N N Tsurikova; N V Voronkova; M I Miminoshvili; D M Braginsky; O N Yastrebova; O B Booynitskaya; O V Isaeva; M I Michailov; A I Archakov Journal: J Viral Hepat Date: 2002-11 Impact factor: 3.728
Authors: Lia L Lewis-Ximenez; Georg M Lauer; Julian Schulze Zur Wiesch; Paulo Sergio Fonseca de Sousa; Cleber F Ginuino; Gláucia Paranhos-Baccalá; Hanno Ulmer; Karl P Pfeiffer; Georg Goebel; João Luiz Pereira; Jaqueline Mendes de Oliveira; Clara Fumiko Tachibana Yoshida; Elisabeth Lampe; Carlos Eduardo Velloso; Marcelo Alves Pinto; Henrique Sergio Coelho; Adilson José Almeida; Carlos Augusto Fernandes; Arthur Y Kim; Alexander M Strasak Journal: Clin Infect Dis Date: 2010-05-01 Impact factor: 9.079
Authors: J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape Journal: Gastroenterology Date: 2003-07 Impact factor: 22.682
Authors: Harald Hofer; Thomas Watkins-Riedel; Oskar Janata; Edward Penner; Heidemarie Holzmann; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci Journal: Hepatology Date: 2003-01 Impact factor: 17.425
Authors: Gerson Dierley Keppeke; Minoru Satoh; Maria Lucia Gomes Ferraz; Edward K L Chan; Luís Eduardo C Andrade Journal: Immunol Res Date: 2014-10 Impact factor: 2.829